Drugs / ABSK131
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07288957 | Jul 2025 → Dec 2028 expected | — | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Abbisko Therapeutics Co, Ltd | Results 2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1 (pan-KRAS) abbisko.com ↗
Results were shared for ABSK112 (EGFR exon20ins inhibitor), ABSK131 (PRMT5*MTA inhibitor), and ABK-KRAS-1 (pan-KRAS inhibitor), as well as results from a study investigating potential resistance mechanisms to KRAS G12C inhibitors. |
| 2025-03-07 | Abbisko Therapeutics Co, Ltd | Regulatory Abbisko Therapeutics Announces IND Clearance for ABSK131, a Novel PRMT5*MTA Inhibitor, from the China CDE abbisko.com ↗
06 March 2025, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the IND application for ABSK131, a highly-selective small molecule inhibitor of PRMT5*MTA. |
| 2024-12-03 | Abbisko Therapeutics Co, Ltd | Regulatory Abbisko Therapeutics Announces U.S. FDA IND Clearance for ABSK131, a Novel PRMT5*MTA Inhibitor abbisko.com ↗
December 3, 2024, Abbisko Therapeutics Co., Ltd. (HKEX: 02256) today announced that the US FDA has cleared the IND application for ABSK131, a highly-selective small molecule inhibitor of PRMT5*MTA. |
| 2024-10-24 | Abbisko Therapeutics Co, Ltd | Results Abbisko presented preclinical research results of its PRMT5* MTA and oral KRASG12D programs at the 36th International Molecular Targets and Cancer Treatment Conference (EORTC-NCI-AACR) abbisko.com ↗
Utilizing structural and computation-aided medicinal chemistry design, we have discovered a potential best-in-class MTA-cooperative PRMT5 inhibitor ABSK131 with improved potency, selectivity, and brain-penetrant ability. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-07-23 | Abbisko Therapeutics Co, Ltd | Abbisko Therapeutics Enrolls First Patient in Phase 1 Clinical Trial for ABSK131, a Novel PRMT5*MTA Inhibitor abbisko.com ↗ |
| 2025-04-28 | Abbisko Therapeutics Co, Ltd | 2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1 (pan-KRAS) abbisko.com ↗ |
| 2025-03-07 | Abbisko Therapeutics Co, Ltd | Abbisko Therapeutics Announces IND Clearance for ABSK131, a Novel PRMT5*MTA Inhibitor, from the China CDE abbisko.com ↗ |
| 2024-12-03 | Abbisko Therapeutics Co, Ltd | Abbisko Therapeutics Announces U.S. FDA IND Clearance for ABSK131, a Novel PRMT5*MTA Inhibitor abbisko.com ↗ |
| 2024-10-24 | Abbisko Therapeutics Co, Ltd | Abbisko presented preclinical research results of its PRMT5* MTA and oral KRASG12D programs at the 36th International Molecular Targets and Cancer Treatment Conference (EORTC-NCI-AACR) abbisko.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABSK131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07288957 ↗ |
| Route | Oral | “patients will orally receive ABSK131 at the recommended dose for expansion (RDE)” NCT07288957 ↗ |